The TCT Geoffrey O. Hartzler Master Operator Award will be presented to Kenneth Rosenfield, MD, MSc, during Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will take place October 25-28, 2025, in San Francisco, California at the Moscone Center.
The TCT 2025 Career Achievement Award will be presented to Stephan Windecker, MD, during Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will take place October 25-28, 2025, in San Francisco, California at the Moscone Center.
The Cardiovascular Research Foundation (CRF) is pleased to announce that registration is now open for TCT 2025 (Transcatheter Cardiovascular Therapeutics庐), the world鈥檚 premier educational symposium in interventional cardiovascular medicine. TCT 2025 will take place October 25-28, 2025, at the Moscone Center in San Francisco, California.
The Cardiovascular Research Foundation (CRF) is pleased to announce the appointment of Josep Rod茅s-Cabau, MD, PhD, as the Editor-in-Chief of Structural Heart: The Journal of the Heart Team, the official journal of CRF. He will succeed Anthony N. DeMaria, MD, who is retiring after having led the journal since its inception in 2017.
CTO Plus 2025 will feature the latest research and techniques for chronic total occlusions (CTO) and complex percutaneous coronary interventions (PCI). The annual conference, organized by the Cardiovascular Research Foundation庐 (CRF庐), will take place February 28 鈥� March 1 at the New York Marriott Marquis in New York, NY. The program guide is available online.
THT 2025 Late-Breaking Clinical Science Unveiled
The Cardiovascular Research Foundation (CRF) is pleased to announce that registration for the second New York Valves: The Structural Heart Summit is now open. Following the outstanding success of last year鈥檚 inaugural conference, New York Valves 2025 is the world鈥檚 premier structural heart meeting and continues its mission to shape the future of structural heart care through collaboration, education, and innovation. The summit will take place June 25-27, 2025, at the Jacob K. Javits Convention Center, North in New York City.
The Cardiovascular Research Foundation庐 (CRF庐) proudly announces the appointment of Dr. Jeffrey Popma as Chief Scientific and Strategic Officer. A world-renowned leader in cardiovascular research, Dr. Popma will drive forward pivotal programs and initiatives that will shape CRF鈥檚 future and fuel innovation at the CRF庐 Clinical Trials Center (CTC). His leadership will be instrumental in the development of the recently launched Real-World Data and Outcomes Center, advancing CRF鈥檚 commitment to impactful research. Additionally, as Program Director for New York Valves and TCT庐 (Transcatheter Cardiovascular Therapeutics庐), CRF鈥檚 flagship scientific meeting, Dr. Popma will play a key role in guiding the organization鈥檚 transformative contributions to the field of cardiovascular medicine.
The Cardiovascular Research Foundation庐 (CRF庐) is pleased to announce that Symbiosis has won the TCT庐 2024 Shark Tank Innovation Competition for its development of an adjustable transcatheter mitral valve replacement (TMVR) system. The competition took place during Transcatheter Cardiovascular Therapeutics庐 (TCT庐), the annual scientific symposium of CRF庐 and the world鈥檚 premier educational meeting specializing in interventional cardiovascular medicine, October 27-30 in Washington, DC. The winner was also presented with the Jon DeHaan Foundation Award for Innovation in Cardiology.
Findings from the first international randomized controlled trial to compare patient outcomes following treatment with large-bore mechanical thrombectomy (LBMT) versus catheter-directed thrombolysis (CDT) for intermediate-risk pulmonary embolism (PE) found that LBMT is superior with respect to the hierarchically-tested aggregated outcome of all-cause mortality, intracranial hemorrhage, major bleeding, clinical deterioration and/or escalation to bailout therapy, and postprocedural ICU admission and length of stay. Findings were reported today at TCT 2024, the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world鈥檚 premier educational meeting specializing in interventional cardiovascular medicine. Results were also published simultaneously in Circulation.
The largest trial to examine the impact of colchicine in acute myocardial infarction (MI) found that both acute and long-term colchicine use did not reduce cardiovascular death, myocardial infarction, stroke, or ischemia-driven revascularization.
Results from the large-scale randomized ECLIPSE trial found that a lesion preparation strategy of routine orbital atherectomy had similar outcomes compared with conventional balloon angioplasty prior to implantation of a drug-eluting stent (DES) in severely calcified coronary arteries.
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS). Findings were reported today at TCT 2024, the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world鈥檚 premier educational meeting specializing in interventional cardiovascular medicine. The results were also published simultaneously in the Journal of the American College of Cardiology.
The EVOLVED trial found that early aortic valve intervention in patients with asymptomatic severe aortic stenosis (AS) and mid-wall myocardial fibrosis on magnetic resonance imaging did not reduce the incidence of the composite primary endpoint of all-cause death or unplanned aortic stenosis hospitalization compared with guideline-directed conservative management. Findings were reported today at TCT 2024, the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world鈥檚 premier educational meeting specializing in interventional cardiovascular medicine. The results were also published simultaneously in the Journal of the American Medical Association.
The first powered randomized trial examining early intervention with transcatheter aortic valve replacement (TAVR) in patients with asymptomatic, severe aortic stenosis (AS) found this strategy to be both a safe and effective alternative to clinical surveillance (CS). Findings were reported today at TCT 2024, the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world鈥檚 premier educational meeting specializing in interventional cardiovascular medicine. Results were also published simultaneously in the New England Journal of Medicine.
The Cardiovascular Research Foundation庐 (CRF庐) is proud to unveil the 2024 SET-10 (Scientific Excellence Top 10), recognizing the academic and medical institutions making the most impactful contributions to interventional cardiovascular research at TCT庐 2024 (Transcatheter Cardiovascular Therapeutics庐), the annual scientific symposium of CRF庐.
As the pace of change accelerates in healthcare, the most pressing questions in cardiovascular medicine demand immediate answers. These challenges and more will be tackled head-on at the third annual TCT庐 MedTech Innovation Forum on Sunday, October 27, at the Walter E. Washington Convention Center in Washington, DC. This full-day event, organized by a partnership among the Cardiovascular Research Foundation庐 (CRF庐), Fogarty Innovation, and the FDA, launches TCT庐 2024. Visionary leaders from across the medtech landscape will convene to explore bold solutions, share pioneering insights, and shape the future of cardiovascular care. The complete program is now available online.
The Cardiovascular Research Foundation (CRF) is pleased to announce the late-breaking clinical trials and science to be featured at TCT 2024.
The Cardiovascular Research Foundation庐 (CRF庐) has announced New York Valves: The Structural Heart Summit will feature 12 Late-Breaking Clinical Trials and Science presentations. New York Valves 2024, the expanded iteration of our renowned annual Transcatheter Valve Therapy (TVT庐) conference, will take place June 5-7, 2024, at the Jacob K. Javits Convention Center, North in New York City.
The TCT Geoffrey O. Hartzler Master Operator Award will be presented to Jeffrey W. Moses, MD, during Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will take place October 27-30, 2024, in Washington, DC, at the Walter E. Washington Convention Center.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 蜜桃传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right